Standardizing of Mesothelioma and Pseudomyxoma Care

  • Ranyell Matheus Spencer Sobreira Batista
  • Thales Paulo Batista


Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a major comprehensive treatment of peritoneal surface malignancies. This multimodal approach has proved to be an effective curative treatment or a salvage therapy for a number of patients suffering from peritoneal surface malignancies and is currently the standard of care for appendiceal epithelial neoplasms and Pseudomyxoma peritonei (PMP) syndrome as well as diffuse malignant peritoneal mesothelioma (DMPM). Unfortunately, practices of CRS/HIPEC are widely variable in terms of technical particularities and antimitotic agents, which have produced heterogeneous and no comparable results. Since no single technique has so far demonstrated its superiority over the others, standardization of such practices may enhance patient outcomes, improve care standards and produce homogeneous data that permits systematic comparisons across all centers that offer this procedure.


Hyperthermia, Induced Peritoneal neoplasms Appendiceal neoplasms Neoplasms, Mesothelial 


  1. 1.
    La L (2015) Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 65(4):284–298Google Scholar
  2. 2.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N et al (2016) What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1125 procedures. J Surg Oncol 113(7):796–803PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI (2014) Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1000 patients. J Am Coll Surg 218(4):573–585PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT et al (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22(5):1686–1693PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Cotte E, Passot G, Gilly FN, Glehen O (2010) Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2(1):31–35PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Witkamp AJ, de Bree E, Van Goethem RZF (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27(6):365–374PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Hettinga JV, Konings AW, Kampinga HH (1997) Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hyperth 13(5):439–457CrossRefGoogle Scholar
  9. 9.
    Zunino B, Rubio-Patiño C, Villa E, Meynet O, Proics E, Cornille A et al (2016) Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene 35(2):261–268PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Pelz JO, Vetterlein M, Grimmig T, Kerscher AG, Moll E, Lazariotou M et al (2013) Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 20(4):1105–1113PubMedCrossRefGoogle Scholar
  11. 11.
    McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ (2013) HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 107(6):591–596PubMedCrossRefGoogle Scholar
  12. 12.
    Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA (2015) Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg 210(3):424–430PubMedCrossRefGoogle Scholar
  13. 13.
    Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth 23(5):431–442CrossRefGoogle Scholar
  14. 14.
    Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, de Mello CA, Takahashi RM, Nakagawa WT, Aguiar S Jr, Lopes A (2016) Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single- center comparative analysis. Ann Surg Oncol 23(4):1294–1301PubMedCrossRefGoogle Scholar
  15. 15.
    Schomas DA, Miller RC, Donohue JH et al (1995) Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience. Am J Pathol 19(12):588–595Google Scholar
  16. 16.
    Guo AT, Li YM, Wei LX (2012) Pseudomyxoma peritonei of 92 Chinese patients: Clinical characteristics, pathological classification and prognostic factors. World J Gastroenterol 18(24):3081–3088PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Brendan MJ (2003) The etiology, clinical presentation and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12:585–603CrossRefGoogle Scholar
  18. 18.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456PubMedCrossRefGoogle Scholar
  19. 19.
    Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ (2016) Peritoneal Surface Oncology Group International. A consensus for classification and pathologic reporting of Pseudomyxoma Peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 40(1):14–26PubMedCrossRefGoogle Scholar
  20. 20.
    Cereser Junior CH, Giordani DSN, Weston AC, Pessini SA, Sugarbaker PH, Meinhardt Junior JG (2015) Ovarian cancer with carcinomatosis: a case report [abstract]. Eur J Surg Oncol 41(suppl 1):S202Google Scholar
  21. 21.
    Surgeons AC (2017) In: Amin MB, Edge S, Greene F et al (eds) AJCC cancer staging manual, 8th edn. Springer International Publishing, New YorkGoogle Scholar
  22. 22.
    Milovanov V, Sardi A, Studeman K, Nieroda C, Sittig M, Gushchin V (2016) The 7th edition of the AJCC staging classification correlates with biologic behavior of mucinous appendiceal tumor with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/ HIPEC). Ann Surg Oncol 23(6):1928–1933PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    López-López V, Cascales-Campos PA, Schneider MA, Gil J, Gil E, Gomez-Hidalgo NR et al (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients. A systematic literature review. Surg Oncol 25(4):378–384PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Alyami M, Lundberg P, Kepenekian V, Goéré D, Bereder JM, Msika S, Lorimier G, Quenet F, Ferron G, TEE al. B-R and RWG (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case- controlled, multicenter study. Ann Surg Oncol 23(suppl 5):737–745PubMedCrossRefGoogle Scholar
  25. 25.
    Yan TD, Morris DL, Shigeki K, Dario B, Marcello D (2008) Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol 98(4):224–227PubMedCrossRefGoogle Scholar
  26. 26.
    Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2014) Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients. Eur J Surg Oncol 40(5):551–520CrossRefGoogle Scholar
  27. 27.
    González-Moreno S, Kusamura S, Baratti D, Deraco M (2008) Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):237–241PubMedCrossRefGoogle Scholar
  28. 28.
    Portilla AG, Shigeki K, Dario B, Marcello D (2008) The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 98(4):228–231PubMedCrossRefGoogle Scholar
  29. 29.
    Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98:263–267PubMedCrossRefGoogle Scholar
  30. 30.
    Verwaal VJ, Kusamura S, Baratti D, Deraco M (2008) The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 98(4):220–223PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20(4):1093–1100PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani P, Ortega-Deballon GOFN for RPM (RENAPE) (2016) Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer 65:69–79PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Baratti D, Kusamura S, Cabras AD, Deraco M (2012) Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 19(5):1416–1424PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Kindler HL (2013) Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book 33:182CrossRefGoogle Scholar
  35. 35.
    Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA (2016) Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol 7(1):3–9PubMedPubMedCentralGoogle Scholar
  36. 36.
    Turner KM, Hanna NN, Zhu Y, Jain A, Kesmodel SB, Switzer RA et al (2013) Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer. Ann Surg Oncol 20(4):1068–1073PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Hemelandu C, Sugarbaker PH (2016) Clinicopathologic and prognostic features in patients with peritoneal metastasis from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 23(5):1474–1480CrossRefGoogle Scholar
  38. 38.
    Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR (2009) Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 100(4):321–328PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Sugarbaker PH (2013) Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Transl Gastrointest Cancer 2(2):54–74Google Scholar
  40. 40.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260PubMedPubMedCentralGoogle Scholar
  42. 42.
    Akaishi E, Teixeira F, Katayama M, Mizumoto N, Costa FP, Buzaid AC, Hoff PM (2009) Peritonectomy for peritoneal carcinomatosis: long-term outcomes from a single Brazilian institution. World J Surg 33(4):835–839PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Rodríguez Silva C, Moreno Ruiz FJ, Bellido Estévez I, Carrasco Campos J, Titos García A, Ruiz López M et al (2017) Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World J Surg Oncol 15(1):51PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A et al (2015) Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 2015:610597PubMedPubMedCentralGoogle Scholar
  45. 45.
    Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F et al (2015) High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery 157(1):72–78PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Raspé C, Flöther L, Schneider R, Bucher M, Piso P (2017) Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol 43(6):1013–1027PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD et al (2015) Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 479(1):23–27PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Schaaf L, van der Kuip H, Zopf W, Winter S, Münch M, Mürdter TE et al (2015) A temperature of 40 °C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC. Ann Surg Oncol 22(Suppl 3):S758–S765PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Rettenmaier MA, Mendivil AA, Gray CM, Chapman AP, Stone MK, Tinnerman EJ et al (2015) Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma. Int J Hyperth 31(4):396–402CrossRefGoogle Scholar
  50. 50.
    Batista TP, Badiglian-Filho L, Leão CS (2016) Exploring flow rate selection in HIPEC procedures. Rev Col Bras Cir 43(6):476–479PubMedCrossRefGoogle Scholar
  51. 51.
    Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G et al (2008) Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol 98(4):242–246PubMedCrossRefGoogle Scholar
  52. 52.
    Kusamura S, Dominique E, Baratti D, Younan R, Deraco M (2008) Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98(4):247–252PubMedCrossRefGoogle Scholar
  53. 53.
    Kusamura S, O’Dwyer ST, Baratti D, Younan RDM (2008) Technical aspects of cytoreductive surgery. J Surg Oncol 98(4):232–236PubMedCrossRefGoogle Scholar
  54. 54.
    Sugarbaker H (2016) Avoiding diverting ileostomy in patients requiring complete pelvic peritonectomy. Ann Surg Oncol 23(5):1481–1485PubMedCrossRefGoogle Scholar
  55. 55.
    Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ (2015) Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking. Eur J Surg Oncol 41(3):392–395PubMedCrossRefGoogle Scholar
  56. 56.
    de Cuba EM, Verwaal VJ, de Hingh IH, van Mens LJ, Nienhuijs SW, Aalbers AG et al (2014) Morbidity associated with colostomy reversal after cytoreductive surgery and HIPEC. Ann Surg Oncol 21(3):883–890PubMedCrossRefGoogle Scholar
  57. 57.
    Maciver AH, Al-Sukhni E, Esquivel J, Skitzki JJ, Kane JM, Francescutti FV (2017) Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS/HIPEC) and perioperative practices: an international survey of high-volume surgeons. Ann Surg Oncol 24(4):923–930PubMedCrossRefGoogle Scholar
  58. 58.
    Mavroudis C, Alevizos L, Stamou KM, Vogiatzaki T, Eleftheriadis S, Korakianitis O et al (2015) Hemodynamic monitoring during heated intraoperative intraperitoneal chemotherapy using the FloTrac/ Vigileo system. Int Surg 100(6):1033–1039PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Colantonio L, Claroni C, Fabrizi L, Marcelli ME, Sofra M, Giannarelli D et al (2015) A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg 19(4):722–729PubMedCrossRefGoogle Scholar
  60. 60.
    Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S et al (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10(8):863–869PubMedCrossRefGoogle Scholar
  61. 61.
    Cascales-Campos PA, Sánchez-Fuentes PA, Gil J, Gil E, López-López V, Rodriguez Gomez-Hidalgo N et al (2016) Effectiveness and failures of a fast track protocol after cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy in patients with peritoneal surface malignancies. Surg Oncol 25(4):349–354PubMedCrossRefGoogle Scholar
  62. 62.
    Cascales Campos PA, Gil Martínez J, Galindo Fernández PJ, Gil Gómez E, Martínez Frutos IM, Parrilla Paricio P (2011) Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol 37(6):543–548PubMedCrossRefGoogle Scholar
  63. 63.
    Dagbert F, Thievenaz R, Decullier E, Bakrin N, Cotte E, Rousset P et al (2016) Splenectomy increases postoperative complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 23(6):1980–1985PubMedCrossRefGoogle Scholar
  64. 64.
    Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L (2015) Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 90(4):301–305PubMedCrossRefGoogle Scholar
  65. 65.
    Davies JM, Barnes R, Miligan D, FBC for S in HWP of the HT (2002) Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2(5):440–443CrossRefGoogle Scholar
  66. 66.
    Foster JM, Gupta PK, Carreau JH, Grotz TE, Blas JV, Gatalica Z et al (2012) Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei. Am Surg 78(2):171–177PubMedPubMedCentralGoogle Scholar
  67. 67.
    Sugarbaker PH (2017) When and when not to perform a right colon resection with mucinous appendiceal neoplasms. Ann Surg Oncol 24(3):729–732PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    González-Moreno S, Sugarbaker PH (2004) Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 91(3):304–311PubMedCrossRefGoogle Scholar
  69. 69.
    Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69–76PubMedCrossRefGoogle Scholar
  70. 70.
    Surveillance, Epidemiology and End Results (2017) Mesothelioma recent trends in SEER incidence rates; 2000–2014.
  71. 71.
    Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED (2008) US mesothelioma patterns 1973–2002: indicators of change and insights into background rates. Eur J Cancer Prev 17(6):525–534PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353(15):1591–1603PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Pillai K, Pourgholami MH, Chua TC, Morris DL (2015) Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. Am J Clin Oncol 38(4):388–394PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12(3):605–621PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BA, Moons KG (2012) Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 107(1):161–164PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Takeshima Y, Amatya VJ, Kushitani K, Inai K (2008) A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 130(5):771–779PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME (1999) Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS (1983) Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1(6):386–391PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23(6):1494–1498PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49(15):3140–3148PubMedCrossRefGoogle Scholar
  81. 81.
    Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468–1473PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103(4):839–849PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly F¸o N, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA (2010) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Gastrointest Oncol 17(10):2720–2727Google Scholar
  85. 85.
    Shetty SJ, Bathla L, Govindarajan V, Thomas PLB (2014) Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 80(4):348–352PubMedPubMedCentralGoogle Scholar
  86. 86.
    González-Moreno S, González-Bayón LA, Ortega PG (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2(2):68–75PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M (2010) Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol 2(1):36–43PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J et al (2014) The American society of peritoneal surface malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 110(7):779–785PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M et al (2011) Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 254(2):294–301PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Batista TP, Sarmento BJQ, Loureiro JF, Petruzziello L, Santos CC et al (2017) A proposal of Brazilian society of surgical oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. Rev Col Bras Cir 44(5):530–544PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ranyell Matheus Spencer Sobreira Batista
    • 1
  • Thales Paulo Batista
    • 2
    • 3
  1. 1.Department of Pelvic SurgeryAC Camargo Cancer CenterSão PauloBrazil
  2. 2.Department of Surgery/OncologyIMIPRecifeBrazil
  3. 3.Department of SurgeryFederal University of PernambucoRecifeBrazil

Personalised recommendations